RESUMEN
A rapid and simple method of high performance liquid chromatography with UV detection for the quantification of vancomycin in artificial perfusion fluid and lung tissue samples has been developed and validated. Chromatographic separation was carried out in a Nucleosil 120 C(18) 5 microm column (length, 15 cm; inner diameter, 0.4 cm) using a mixture of 0.05 M NH(4)H(2)PO(4) (pH 4)-acetonitrile (92:8, v/v) as the mobile phase at a flow rate of 1 mL/min, with UV detection at 220 nm. The method used for the vancomycin quantification showed linearity for concentration ranges of 0.1-2, 2-15 and 15-250 microg/mL, with r(2)=0.9985, 0.9996 and 0.9985, respectively. The limit of quantification of the method was 0.1 microg/mL and the coefficients of variation of the between- and within-day precision showed values between 0.6% and 7.0%. The retention time of vancomycin was 8.5 min. The method was used successfully to study the pharmacokinetics of vancomycin in isolated rat lung after its administration through the systemic and inhalatory routes.
Asunto(s)
Antibacterianos/análisis , Antibacterianos/farmacocinética , Cromatografía Líquida de Alta Presión/métodos , Vancomicina/análisis , Vancomicina/farmacocinética , Acetonitrilos/química , Animales , Calibración , Cromatografía Líquida de Alta Presión/instrumentación , Estabilidad de Medicamentos , Congelación , Guías como Asunto , Concentración de Iones de Hidrógeno , Fosfatos/química , Fenómenos Fisiológicos , Ratas , Estándares de Referencia , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Factores de TiempoRESUMEN
The aim of our present work was to establish the effect of the osmolality of the hypotonic buffer on the encapsulated amount and the in vitro properties of Amikacin-loaded erythrocytes. Amikacin was encapsulated in rat erythrocytes using a hypotonic dialysis method with hypotonic buffers of different osmolalities with mean values around 90 and 150 mOsm/kg. Morphological examination of the ghost erythrocytes was accomplished using scanning electron microscopy (SEM). The osmotic fragility of normal and loaded erythrocytes was tested using hypotonic solutions. Evaluation of the hematological parameters of the control and loaded erythrocytes was carried out using a hematology system analyzer. Amikacin release from loaded erythrocytes was tested in autologous plasma at 37 degrees C over a 24-h period. The quantification of Amikacin in loaded erythrocytes and in autologous plasma was performed using an HPLC technique. A higher osmotic fragility of loaded erythrocytes was observed using a low osmolality buffer. Some hematological parameters showed statistically significant differences between the loaded erythrocytes obtained using two buffers of different osmolalities with respect to untreated erythrocytes. According to our results, Amikacin carrier erythrocytes obtained by hypotonic dialysis using a low osmolality buffer (90 mOsm/kg) should afford a good encapsulation yield, appropriate morphological properties, and sustained release in vitro.
Asunto(s)
Amicacina/química , Antibacterianos/química , Portadores de Fármacos/química , Eritrocitos/química , Amicacina/metabolismo , Animales , Antibacterianos/metabolismo , Química Farmacéutica , Diálisis , Portadores de Fármacos/metabolismo , Índices de Eritrocitos , Membrana Eritrocítica/química , Membrana Eritrocítica/metabolismo , Eritrocitos/metabolismo , Hemólisis , Soluciones Hipotónicas , Técnicas In Vitro , Masculino , Concentración Osmolar , Fragilidad Osmótica , Ratas , Ratas Wistar , Factores de TiempoRESUMEN
Vancomycin dispositions in the respiratory system were compared after systemic and inhalatory administration under two respiratory conditions using the isolated-lung model. Inhalatory delivery led to much higher drug levels in pulmonary tissue and fluids. The respiratory pattern affects vancomycin disposition in the pulmonary system regardless of the administration route.
Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Pulmón/metabolismo , Vancomicina/administración & dosificación , Vancomicina/farmacocinética , Administración por Inhalación , Animales , Área Bajo la Curva , Líquidos Corporales/efectos de los fármacos , Líquidos Corporales/metabolismo , Líquido del Lavado Bronquioalveolar/química , Técnicas In Vitro , Masculino , Alveolos Pulmonares/efectos de los fármacos , Alveolos Pulmonares/metabolismo , Ratas , Ratas Wistar , Respiración Artificial , Mecánica Respiratoria/fisiologíaRESUMEN
OBJECTIVES: To characterize the distribution of linezolid in lung when it accesses this organ from the systemic circulation and when administered through the pulmonary route and to evaluate the influence of the 'respiratory mode' in the pulmonary distribution for both routes. METHODS: The study was conducted with 24 Wistar rats divided into four groups treated with linezolid under different experimental conditions. After the animals had been subjected to a tracheotomy followed by mechanical ventilation, the lungs were isolated. After a 5 min stabilization period, the antibiotic was administered through the systemic or the pulmonary route and samples of efferent fluid (EF) were collected using a previously programmed fraction collector. Samples of bronchoalveolar fluid (BALF) and of lung tissue were also taken at the end of each experiment. The concentrations of linezolid in the samples were determined using an HPLC technique with UV detection. RESULTS: The administration of linezolid through the inhalatory route significantly increased the levels of the drug in lung tissue and BALF with lung tissue/EF partition coefficients of 8.33 +/- 2.51 as compared with 1.90 +/- 0.78 for systemic administration. Also, the decrease in respiratory rate together with the increase in tidal volume favoured the process of linezolid distribution in pulmonary tissues and fluids. CONCLUSIONS: Administration through the pulmonary route affords and excellent method for passively vectoring linezolid to the pulmonary fluids and tissues and the respiratory mode seems to affect the disposition of the antibiotic in this tissue for both administration routes.
Asunto(s)
Acetamidas/administración & dosificación , Acetamidas/farmacocinética , Antiinfecciosos/administración & dosificación , Antiinfecciosos/farmacocinética , Pulmón/metabolismo , Oxazolidinonas/administración & dosificación , Oxazolidinonas/farmacocinética , Administración por Inhalación , Animales , Líquido del Lavado Bronquioalveolar , Linezolid , Masculino , Ratas , Ratas Wistar , Distribución TisularRESUMEN
A study was carried out to evaluate the potential pharmacokinetic interaction between digoxin and acenocoumarol. The binding of digoxin to rabbit cardiac tissue homogenates was assessed in vitro, using the equilibrium dialysis technique. An increase in the first-order constant (p<0.05) and a reduction in the partition coefficient in the equilibrium situation (p<0.001) of digoxin were observed when the cardiac homogenates were previously treated with acenocoumarol. In the in vivo study, the kinetics of digoxin administered in single and multiple dosage regimens were compared in control rabbits and in rabbits treated simultaneously with acenocoumarol. Kinetic analysis of the results was performed using Non-linear Mixed Effects Modeling (NONMEM). In the presence of acenocoumarol, the population distribution volume (Vd) of digoxin was increased by 40-60%, no differences being found as regards the elimination clearance. Also, joint administration of both drugs led to a reduction in digoxin concentrations in the heart (p<0.01) at the end of the dosage regimen. Both sets of results point to the hypothesis of a hitherto unreported possible pharmacokinetic interaction between the two drugs affecting the distribution process. This interaction could lead to lower plasma digoxin levels, in view of the increased Vd, and a possible reduction in the therapeutic effect, owing to the decrease in affinity and in concentration in heart tissue.